I had another look at Chris Judd interview with Michael Goldberg...

I had another look at Chris Judd interview with Michael Goldberg (Collins St Value Fd). A few points that were interesting and new to me:
1. Hayfever efficacy: eventhough the hayfever clinical trials failed for iPPS, there seems pre-clinical results were overwhelming, hence PAR will have another look at it I think (Paul Rennie alluded to this at the AGM, but after successful OA), and it seems like they now know why the clinical trial failed according to Michael, so this is great news for another condition to be treated.
2. Better than 90% of patients that use iPPS say it reduces pain and effective. Recall this is more than 50% Pain score which was the primary endpoints, so this fills in the gap that Paul mentioned in the AGM ie the results were better than the Phase 2b results.
3. Emphasis on the supply side of iPPS/patent agreement -Bene Pharma. Notice Paul emphasized this pt at the AGM. Bene Pharma is the only FDA approved supplier, (this was highlighted by previous research by FiftyOne Capital).
4. iPPS is now seen as the healer of OA disease - from purely reducing pain to fixing the source of the problem (reduce BML lesions, reduce biomarkers).
5. $2000-$2500 per treatment for OA - heard through the grapevine from Michael
6. Partner potential is for a marketing/distributor partnership, Michael is pretty confident on iPPS efficacy, he seems to think this is done deal - PAR wont need help in proving efficacy but just distribution from biopharma partner.